< Back to search
Filter
1
Featured

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

for
Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
Location: Philadelphia PA, Fairfax VA, Cleveland OH,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07490301

Phase2, Phase3, Recruiting
Featured

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

for
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma,
Location: San Antonio TX
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06084481

Phase1, Recruiting
Featured

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

for
Non-cystic Fibrosis Bronchiectasis,
Location: Chapel Hill NC, Pittsburgh PA, Birmingham AL,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT06603246

Phase1, Recruiting
Featured

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non Small Cell Lung Cancer
Location: Levis, Greenfield Park, Montreal, Brampton,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT04928846

Phase3, Recruiting
Featured

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

for
Non-Small Cell Lung Cancer
Location: New Haven CT, Mineola NY, The Bronx NY, New York NY,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05789082

Phase1, Phase2, Recruiting

Interested in new pancreatic cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Featured

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non-Small Cell Lung Cancer
Location: New Haven CT, Westbury NY, The Bronx NY, Teaneck NJ,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06568939

Phase2, Recruiting
Featured

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for
Non-small Cell Lung Cancer
Location: Boston MA, New Haven CT, Lebanon NH, New York NY,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT04302025

Phase2, Recruiting
Featured

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer
Location: Lebanon NH, East Brunswick NJ, Rockledge FL, Brampton,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07155187

Phase2, Phase3, Recruiting
Featured

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

for
Small Cell Lung Cancer
Location: Boston MA, Bethlehem PA, Fairfax VA, Winchester VA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07365241

Phase3, Recruiting
Featured

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non-Small Cell Lung Cancer
Location: Winter Haven FL, Athens GA, Cincinnati OH, Lexington KY,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06236438

Phase2, Phase3, Recruiting
Featured

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

for
Small Cell Lung Cancer
Location: Boston MA, New Haven CT, Fairfax VA, Ocala FL, Tampa FL,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07155174

Phase2, Recruiting
Featured

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Location: Rimouski, Boston MA, Worcester MA, Hartford CT, Quebec,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06793215

Phase3, Recruiting
Featured

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

for
Mature B-Cell Non-Hodgkin Lymphoma
Location: Boston MA, New York NY, Baltimore MD, Cincinnati OH,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 0 - 30

Code: NCT05533775

Phase1, Phase2, Recruiting
Featured

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

for
Non Small Cell Lung Carcinoma
Location: Boston MA, Shirley NY, East Brunswick NJ, Easton PA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06772623

Phase1, Phase2, Recruiting
Featured

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

for
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Location: Boston MA, Albany NY, Virginia Beach VA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06806033

Phase2, Recruiting
Featured

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

for
Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Location: St. John's, Moncton, Kingston, Greater Sudbury,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06830759

Recruiting
Active & Responsive

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

for
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC,
Location: New York NY, Belleville NJ, Philadelphia PA, Newark DE,
Sponsor: Immuneering Corporation

Sex: All

Age: 18+

Code: NCT07562152

Phase3, Recruiting
Active & Responsive

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver,
Location: Scarborough ME, Worcester MA, Hartford CT, Norwalk CT,
Sponsor: Massive Bio, Inc.

Sex: All

Age: 0+

Code: NCT03452774

Recruiting
Active & Responsive

Increasing Germline Genetic Testing for Patients With Cancer

for
Hereditary Pancreatic Cancer, Conditions or Focus of Study,
Location: Danville PA, Durham NC, Salisbury NC, Orlando FL,
Sponsor: Josh Peterson

Sex: All

Age: 0+

Code: NCT07307664

Recruiting
Active & ResponsiveNew

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

for
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC,
Location: Tampa FL
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT07805954

Phase3, Recruiting